Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (131-140 of 218) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
Journal of Neuro-Oncology|January 9, 2016
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemJohannes van de Nes, Marco Gessi, Antje Sucker, et al.
Frontiers in Oncology|June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG StudyKatharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.
European Heart Journal|August 14, 2021
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyLars Michel, Iris Helfrich, Ulrike Barbara Hendgen-Cotta, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
International Journal of Cancer|June 23, 2022
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.
Pageof 22

Showing results (131-140 of 218) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
Journal of Neuro-Oncology|January 9, 2016
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemJohannes van de Nes, Marco Gessi, Antje Sucker, et al.
Frontiers in Oncology|June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG StudyKatharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.
European Heart Journal|August 14, 2021
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyLars Michel, Iris Helfrich, Ulrike Barbara Hendgen-Cotta, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
International Journal of Cancer|June 23, 2022
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.
Pageof 22